Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ocular Therapeutix, Inc.
With
Fortrea
Duke University
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Treatment naïve for Neovascular Age-Related Macular Degeneration (nAMD) in either eye at screening.
Are at least older than 50 years of age at Day 1.
Have Best Corrected Visual Acuity (BCVA) of at least 84 Early Treatment Diabetic Retinopathy Study (ETDRS) letter score (approximate 20/20 Snellen equivalent) at Day 1; OR have an increase of at least 10 ETDRS letters of Best Corrected Visual Acuity (BCVA) from Screening (Visit 1) BCVA
You may not be if
Monocular subjects or a Best Corrected Visual Acuity (BCVA) score of 20/200 in fellow eye at screening.
Have evidence of a scar, fibrosis, or atrophy of \> 50% of the total lesion in the study eye.
Clareo Health | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
